


Vital Therapies®, Inc. (VTL) is a cellular therapy company dedicated to improving the lives of people with liver disease through the development of the ELAD® System, an extracorporeal human hepatic cell-based liver treatment (hereafter referred to as the ELAD® System or ELAD). ELAD is designed to promote the recovery and regeneration of the patient's failing liver, and potentially increase the rate of survival from acute forms of liver failure. The ELAD System incorporates approximately 440 grams of our human liver-derived cells, or VTL C3A cells, contained in four hollow-fiber cartridges, that are combined with disposable components and a reusable delivery device. During treatment with ELAD, blood is drawn from the patient via a central venous line and then passes into the delivery device where plasma ultrafiltrate is isolated. The patient's plasma ultrafiltrate then passes through hollow fibers contained within the four cartridges, where semipermeable fibers permit bidirectional flow between the VTL C3A cells and the ultrafiltrate. *In vitro* research suggests that VTL C3A cells add proteins to the ultrafiltrate, and may remove substances typically metabolized by the liver. Treatment is expected to consist of a single, continuous session lasting between three and five days, as determined by the treating physician.

Our Proprietary VTL C3A Cells The active ingredient within the ELAD C3A cell cartridges is the hepatoblastoma-derived, C3A cell line (VTL C3A cells), a subclone of the human hepatoblastoma cell line HepG2. VTL C3A cells are maintained in VTL's proprietary cell banks, which have been subjected to rigorous safety testing for adventitious agents in accordance with regulatory guidance documents.

VTL C3A cells are being evaluated to determine whether they may help to stabilize patients and restore host defense mechanisms by providing acute-phase response proteins, thereby dampening inflammation, and encouraging liver regeneration by providing soluble factors known to be associated with liver repair. We are also investigating whether these cells have the potential to address coagulopathies that are common in alcoholic hepatitis patients, and whether they may help in the restoration of liver function by providing liver-specific metabolism and detoxification capabilities. VTL C3A cells can be stored, and shipped worldwide.



ELAD Cartridge Cross-section (40X)

As part of ELAD's clinical development program, more than 250 subjects globally have received treatment with the ELAD System through prior clinical trials and a compassionate use program. Although VTI-208, our Phase 3 clinical trial evaluating ELAD in alcohol-induced liver decompensation, failed to reach either the primary or secondary endpoints, data from pre-specified and post-hoc analyses of this study has shown trends that may indicate a potential to increase survival rates in certain subsets of subjects with liver failure due to acute hepatocellular insult and alcohol use.

In March 2018, the company completed enrollment for a Phase 3 trial in severe alcoholic hepatitis, known as VTL-308. The company is expecting to report top-line results in third quarter of 2018.

ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure.



The ELAD System has not been demonstrated to be safe or effective for any indication and is not available for sale in the United States or any other country. CAUTION: Investigational Product. Limited by United States law to investigational use.

Management Team

Russell J. Cox
Chief Executive Officer

Duane Nash, M.D., J.D., M.B.A.
President

Robert A. Ashley, M.A.
Chief Technical Officer,
Executive Vice President

Michael V. Swanson, M.B.A.
Chief Financial Officer,
Executive Vice President

John Dunn
General Counsel

Andrew Henry
Vice President of Clinical Operations

Richard Murawski
Vice President of Manufacturing

Aron P. Stern, M.B.A.
Chief Administration Officer

Albert Kildani
Vice President of Investor Relations
and Business Development

For more information please visit
www.vitaltherapies.com or contact
us directly at 858-678-6840

ELAD[®]
SYSTEM

Vital Therapies holds multiple patents in the US and across the world.

SELECTED PUBLICATIONS

- Thompson JA, Jones N, Al-Khafaji A, et al. Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis - A Multinational, Prospective, Controlled, Randomized Trial. *Liver Transplantation* 2017; 24: 380-393.
- Mac Nicholas R, Subramanian R, Thompson J, Al-khafaji A, Reich D, Hassanein T, Teperman L, Li Z, Ashley R. Phosphatidylethanol (PEth) in Blood as Marker of Alcohol Relapse (AR) in Subjects with Severe Alcoholic Hepatitis (sAH) in the ELAD Phase 3 Clinical Trial. *Hepatology* 2016; 64: 142A
- Bedard P, Van Allen J, Heredia N, Michalopoulos G, Landeen L. ELAD VTL C3A Cells May Impact Liver Regeneration Through Secreted Factors. *Journal of Hepatology* 2015; 62: 1071A
- Landeen L, Van Allen J, Heredia N, Lapetoda J, Bedard P, Brotherton J, Ashley R, Dinarello C. Expression of Acute-Phase Proteins by ELAD C3A Cells. *Transplantation* 2015; 99, Number 7S; 208-208
- Ashley R, Stange J, Henry A, Li Z. A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD Human Cell-Based Bio-Artificial Liver Support System (ELAD) in Subjects with Alcohol-Induced Liver Decompensation (ALD). *Journal of Hepatology* 2015; 62: S844-S845
- Landeen L, Lapetoda J, Van Allen J, Heredia N, Brotherton J, Ashley R. Expression of Liver-Specific Cytochrome P450 Isoenzymes and Oxygenases in C3A Cells Prior To and After Treatment with the ELAD Liver Support System. *Journal of Hepatology* 2015; 62: S764-S764
- Teperman L, Brotherton J, Eggert M, Dominik A, Stange J. Protein Content Assessment During Treatment with the ELAD Bioartificial Liver Support System. *Transplantation* 2014; 98: 301-301
- Teperman L. Bilirubin Improvement Correlates with 90-Day Survival with Use of the ELAD System in a Randomized, Controlled Study of Subjects with Acute Alcoholic Hepatitis or Acute Decompensation of Cirrhosis. *American Journal of Transplantation* 2013; 13, Issue S5: 74-74
- Teperman L. A phase 2b study of safety & efficacy in subjects with acute-on-chronic hepatitis (AOCH) due either to acute alcoholic hepatitis or acute decompensation of cirrhosis & the use of a support system (ELAD) a human cell-based biological liver. *American Journal of Transplantation* 2012;12:64-64
- Teperman L. A Phase 2b Study of Safety & Efficacy of a Human Cell-Based Biological Liver Support System (ELAD (R)) in Subjects with Acute-on-Chronic Hepatitis (AOCH) Due Either to Acute Alcoholic Hepatitis or Acute Decompensation of Cirrhosis. *Liver Transplantation* 2012;18 1 1:S82-S82
- Hillebrand DJ, Frederick RT, Williams WW, Brown Jr. RS, Napotilano LM, Te HS, Millis JM, Ashley RA, Pockros PJ. Safety and Efficacy of the extracorporeal liver assist device (ELAD) in patients with acute on chronic liver failure. *Journal of Hepatology* 2010;52:S323-S324
- Duan Z, Xin S, Zhang J, You S, Millis JM. 3-year follow up of acute-on-chronic liver failure (ACLF) subjects in a randomized, controlled, multicenter trial of the ELAD Bioartificial Liver Support System in 49 Chinese subjects reveals significant transplant-free survival (TFS) benefit. *Hepatology* 2010; 52:S1:1089
- Brotherton J, He D, Asslani S, Millis JM. ELAD Cellular and System Performance Improvements. *Hepatology* 2007;46:4:615A
- Filippi C, Keatch SA, Ranger D, et al. Improvement C3A cell metabolism for usage in bioartificial liver support systems. *J Hepatology* 2004; 41:599-605
- Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, Maguire P. Initial Experience With The Modified Extracorporeal Liver-Assist Device For Patients With Fulminant Hepatic Failure: System Modifications And Clinical Impact. *Transplantation* 2002; 74:1734-1746
- Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, Williams R. Pilot-Controlled Trial of the Extracorporeal Liver Assist Device in Acute Liver Failure. *Hepatology* 1996; 24:1446-1451
- Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix Extracorporeal Liver Assist Device: Initial Clinical Experience Artificial Organs 1994; 18:390-396
- Sussman NL, Chong MG, Koussayer T, He DE, Shang TA, Whisenand HH, Kelly JH. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. *Hepatology*, 1992; 16:60-65
- Kelly JH, Koussayer T, He D, et al. An improved model of acetaminophen-induced fulminant hepatic failure in dogs. *Hepatology* 1992; 15:329-335
- American Type Culture Collection (ATCC), C3A cell line deposit, number CRL-10741



VITAL THERAPIES, INCORPORATED | 15010 Avenue of Science, Suite 200 | San Diego, California 92128
(858) 673-6840 | info@vitaltherapies.com | www.vitaltherapies.com

The ELAD System has not been demonstrated to be safe or effective for any indication and is not available for sale in the United States or any other country. CAUTION: Investigational Product. Limited by United States law to investigational use.

Scientific Advisory Board

Clifford J. Steer, M.D.
Chair of Scientific Advisory Board
Professor of Medicine and Genetics,
Cell Biology, and Development
University of Minnesota Medical School

Fernando Camargo, Ph.D.
Professor
Stem Cell Program,
Boston Children's Hospital
Department of Stem Cell Biology,
Harvard University
Principal Member,
Harvard Stem Cell Institute

Charles Dinarello, M.D.
Professor of Medicine and Immunology
University of Colorado
Professor of Experimental Medicine
Radboud University
Nijmegen, The Netherlands

Alan Hofmann, M.D.
Professor Emeritus of Medicine
University of California, San Diego

George K. Michalopoulos, M.D.
Professor and Chair
Department of Pathology
University of Pittsburgh School of Medicine

J. Michael Millis, M.D.
Professor of Hepatobiliary Surgery
University of Chicago

**Nikolaos T. Pyrsopoulos, MD, PhD,
MBA, FACP, AGAF, FAASLD, FRCP
(Edin)**
Professor and Chief,
Division of Gastroenterology
and Hepatology
Medical Director Liver Transplantation
Rutgers- New Jersey Medical School
University Hospital